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Abstract
Airway epithelial CD55 down-regulation occurs in several hypoxia-
associated pulmonary diseases, but the mechanism is unknown.
Using in vivo and in vitro assays of pharmacologic inhibition and
gene silencing, the current study investigated the role of hypoxia-
inducible factor (HIF)-1a in regulating airway epithelial CD55
expression. Hypoxia down-regulated CD55 expression on small-
airway epithelial cells in vitro, and inmurine lungs in vivo; the latter
was associated with local complement activation. Treatment with
pharmacologic inhibition or silencing of HIF-1a during hypoxia-
recovered CD55 expression in small-airway epithelial cells. HIF-1a
overexpression or blockade, in vitro or in vivo, down-regulated
CD55 expression. Collectively, these data show a key role
for HIF-1a in regulating the expression of CD55 on airway
epithelium.
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Clinical Relevance
Previous studies have reported that down-regulation of CD55, a
complement regulatory protein, expressed on airway epithelium
was associated with local complement activation in idiopathic
pulmonary ﬁbrosis and obliterative bronchiolitis. However, the
molecular mechanisms mediating this airway epithelial CD55
down-regulation remain unknown. The data show a central role
for hypoxia-inducible factor (HIF)-1a in mediating down-
regulation of airway epithelial–derived CD55. These data suggest
that local complement activation in hypoxia-associated
pulmonary diseases may, in part, be mediated by HIF-
1a–dependent down-regulation of airway epithelial CD55. This
report provides insight on a potential therapeutic intervention for
attenuating complement-mediated injuries in hypoxic pulmonary
diseases by preserving airway epithelial CD55 expression.
Hypoxia is a complicating factor in several
pulmonary diseases, such as obliterative
bronchiolitis (OB) and idiopathic
pulmonary ﬁbrosis (IPF) (1, 2).
Physiological changes involved in both of
these pulmonary diseases are driven by
complex interplay between innate and
adaptive immunity, along with many other
hypoxia-mediated molecular mechanisms
of the immune system. Our group reported
novel roles for complement activation in
OB and IPF, due to complement-mediated
cytotoxicity on airway epithelium (3–5).
These ﬁndings correlated with airway
epithelial CD55 down-regulation, a key
complement regulatory protein (CRP) in
OB and IPF (3, 5).
CD55 is a glycosylphosphatidylinositol-
anchored protein present on various
cell types, including murine and human
airway epithelial membranes (6), and
functions by regulating complement
activation via dissociation of complement
C3 and C5 convertases (6). Accordingly,
airway epithelial CD55 could protect
against lung diseases associated with
complement activation. However,
mechanisms regulating CD55 in
pulmonary pathologies have not been
deﬁned.
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Because CD55 is down-regulated on
cell membranes of transplanted airway
epithelium and in pulmonary ﬁbrosis (3, 5),
we hypothesized that tissue hypoxia, a
condition common to both diseases, may
mediate CD55 down-regulation. In
particular, we hypothesize that hypoxia-
inducible factor (HIF)-1a, a transcription
factor induced potently by hypoxia (7),
regulates airway epithelial CD55 expression,
as indicated by small-airway epithelial cells
(SAECs) and murine lungs. Data in the
current study show a crucial role for HIF-1a
in regulating CD55 expression on airway
epithelium in vitro and in vivo.
Materials and Methods
Animals
C57BL/10 male mice (Harlan, Indianapolis,
IN) were housed in Laboratory Animal
Resource Center at Indiana University School
of Medicine (Indianapolis, IN), according to
institutional guidelines. Studies were approved
by Indiana University School of Medicine
Institutional Care and Use Committee (3).
Cells
SAECs were from Lonza Clonetics
(Walkersville, MD).
Hypoxia
Mice were placed in a custom-made hypobaric
hypoxia chamber (10% O2) for 24 hours, as
previously reported (8). SAECs were incubated
in 1% O2 hypoxic chamber (The Baker Co.,
Ruskinn Technology Ltd., Sanford, ME) for
various time points (8). Mice and SAECs were
exposed to 21% O2 for normoxia (9).
HIF-1a Inhibition
HIF-1a was pharmacologically inhibited by
pretreating SAECs with 100 nM chetomin
and vehicle control (Sigma-Aldrich,
St. Louis, MO), or by intratracheal instillation
of mice with 1 mg/ml chetomin and vehicle
control. Additional details are available in the
online supplement.
RNA Interference
SAECs were transfected with 50 nM of
human HIF-1a small interference RNA
(siRNA; M-004018-05-0005; Dharmacon
Technologies, Pittsburgh, PA), or control
siRNA (D-001600-01-05; Dharmacon
Technologies). Mice were intratracheally
instilled with 50 mg of mouse HIF-1a
siRNA (L-040638-00-0005; Dharmacon
Technologies), or control siRNA.
Additional details are available in the
online supplement.
HIF-1a Stabilization
SAECs were treated with 1 mM
dimethyloxaloylglycine (DMOG; Sigma-
Aldrich) and vehicle control. Mice were
intratracheally instilled with vehicle control
or 1 mg/ml DMOG. Additional details are
available in the online supplement.
Adenoviral Transduction
Normoxic SAECs were transduced with
50 plaque-forming units per cell AdCA5 or
AdLACZ vectors (10).
Immunoblot
Cytoplasmic/Nuclear Extraction (Thermo
Fisher Scientiﬁc, Rockford, IL) was used
to detect cytoplasmic CD55 and nuclear
HIF-1a in SAECs and mouse lung
homogenates. Antibodies for immunoblots
included: CD55 (sc-9156 [H-319]; Santa
Cruz Biotechnology, Santa Cruz, CA);
HIF-1a (cat. no. AF1935; R&D Systems,
Minneapolis, MN), vinculin (ab18058;
Abcam, Cambridge, MA), lamin b1
(ab16048; Abcam), and b-actin (ab8224;
Abcam). Immunoblot analysis was
performed as previously described (5).
Real-Time Polymerase Chain
Reaction
Total RNA and cDNA were prepared as
previously described (11). Taqman
mastermix and primers (Applied
Biosystems Life Technologies, Grand
Island, NY) were used. Mouse primers
included: CD55 Mm00438377_m1,
HIF-1a Mm00468869_m1, and b-actin
Mm00607939_s1. The human primers
included: CD55 Hs00892618_m1,
HIF-1a Hs00153153_m1, and b-actin
Hs01060665_g1 (3). Relative gene
expression was completed as previously
described (3).
Immunohistochemistry
CD55 staining was achieved by 1:100
dilution of rabbit anti-human CD55
(sc-31208, Santa Cruz Biotechnology) as
previously described (3, 5). The antigen
retrieval was done by 1M EDTA in a
pressure cooker. The secondary antibody
was donkey-anti-goat (1:100) for 60 min
from Jackson Immunology/Research Labs.
For HIF-1a staining, HIF-1a antibody at
1:100 dilution (NB.100-479; Novus
Biologicals, Littleton, CO) was used. Dako’s
DAKO Envision1 Rabbit was used for HIF-
1a (Dako North America Inc., Carpinteria,
CA). Additional details are available in
the online supplement. Images were
captured with Olympus BX41 microscope
and DP12 camera (Olympus Imaging
America Inc., Melville, NY).
C3a ELISA
Optical density was analyzed at 450 nm on
SpectraMax Plus Softmax Pro 3.1.2 software
(Molecular Devices, Sunnyvale, CA) for
C3a Mouse ELISA (MBS703819; MyBioSource
Inc., San Diego, CA).
Statistical Analysis
One-way ANOVA (Bonferroni), two-tailed
paired t test, and unpaired t test were
performed using GraphPad Prism 4
(GraphPad Prism Software, San Diego,
CA). Data represent mean (6SEM).
Statistical signiﬁcance was set at P, 0.05.
Results
Hypoxia Induces HIF-1a and
Down-Regulates CD55 Expression
Hypoxia is the most potent inducer of
HIF-1a in several tissues, but its induction
in normal human SAECs has not been
reported. Hypoxia induced a time-
dependent induction of HIF-1a in SAECs
(Figures 1A and 1B, P, 0.05). Data
showing concurrent induction of carbonic
anhydrase IX (CA9), an HIF-1a–dependent
gene (12, 13), demonstrated that
hypoxia-induced HIF-1a was active
transcriptionally (Figure 1C). Notably, CD55
transcripts were down-regulated within
6 hours of hypoxia in SAECs (Figure 1D,
P, 0.05), which is the same time point at
which HIF-1a was induced. However, CD55
protein down-regulation occurred at 72 hours
of hypoxia (Figures 1E and 1F, P, 0.05).
Inhibition of HIF-1a Restores CD55
Expression in Hypoxic Human SAECs
In preliminary studies, SAECs from
multiple donors were studied to determine
the time course of hypoxia-induced CD55
down-regulation. Whereas Figures 1E
and 1F depict CD55 down-regulation at
72 hours of hypoxia, in subsequent studies,
hypoxia-induced down-regulation of CD55
protein expression was maximal at 24 hours
due to donor-dependent variations in
SAECs from multiple donors used in these
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experiments. Therefore, the 24-hour time
point was used in all subsequent
experiments. To determine the linkage
between HIF-1a expression and CD55
down-regulation, HIF-1a was
pharmacologically inhibited or silenced
through the use of chetomin or HIF-1a
siRNA, respectively. Vehicle treatment had
no effect on hypoxia-induced down-
regulation of CD55 (see Figure E1A in the
online supplement). Chetomin treatment
signiﬁcantly recovered CD55 transcript
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Figure 1. Hypoxia induces hypoxia-inducible factor (HIF)-1a in small-airway epithelial cells (SAECs) and down-regulates CD55. SAECs were
exposed to hypoxia (1% O2) at times shown. Normoxic (21% O2) cells were controls. (A) Hypoxic SAECs were probed for HIF-1a. Lamin b1 served
as an internal loading control. (B) Densitometry analysis indicated significant up-regulation of HIF-1a by 6 hours of hypoxia versus normoxic
untreated (0 hour controls) conditions. Data are representative of means (6SEM); n = 5; *P, 0.05 versus normoxia; one-way ANOVA with
Bonferroni posttest. (C) CA9 transcripts increased with hypoxia exposure compared with normoxia. Data represent means (6SEM); n = 3; *P,
0.05 or **P, 0.01 versus normoxia; one-way ANOVA with Bonferroni posttest. (D) CD55 transcripts were significantly down-regulated by 6 hours
of hypoxia compared with the controlled normoxic conditions. Values represent means (6SEM); n = 3; *P, 0.05 versus normoxia; one-way
ANOVA with Bonferroni posttest. (E) Hypoxic SAECs were probed for CD55. Vinculin was the internal loading control. (F) Densitometry analysis
shows significant down-regulation of CD55 by 72 hours of hypoxic versus normoxic conditions. Data represent means (6SEM); n = 3; *P, 0.05
versus normoxia; one-way ANOVA with Bonferroni posttest. A.U., absorbance units.
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expression as compared with 6-hour
hypoxia or vehicle controls (Figure E1A,
P, 0.001). Similar to prior reports (14),
preliminary studies conﬁrmed that 100 nM
was the optimal dosing for chetomin-
mediated effects (Figure E2A). Chetomin
restored CD55 protein expression at
24 hours of hypoxia as compared with hypoxic
vehicle controls (Figures E1B and E1C,
P, 0.05). To conﬁrm the HIF-1a–speciﬁc
effects of chetomin, we assessed
transcription of HIF-1a–dependent gene,
CA9 (12, 13). CA9 transcripts were down-
regulated in chetomin-treated, 6-hour
hypoxic SAECs compared with 6-hour
hypoxic SAECs in the presence of vehicle
control, as well as in normoxic conditions
(Figure E1D, P, 0.05).
Gene silencing via siRNA was used
to assess the role of HIF-1a on CD55
expression in hypoxic conditions. Control
experiments conﬁrmed the efﬁcacy of
siRNA to block HIF-1a expression (Figures
2A and 2B, P, 0.05). To further conﬁrm
HIF-1a silencing and its transcriptional
activity, CA9 transcripts were also assessed.
CA9 expression was down-regulated in
hypoxic SAECs transfected with HIF-1a
siRNA compared with 6-hour hypoxic
SAECs transfected with or without control
siRNA and control normoxic cells
(Figure 2C, P, 0.01). CD55 transcripts
were restored within 6 hours of hypoxia
in cells silenced with HIF-1a siRNA
compared with normoxic cells or cells
transfected with the control siRNA in
hypoxic conditions (Figure 2D, P, 0.05).
Notably, silencing HIF-1a also recovered
CD55 protein expression in hypoxic SAECs
compared with normoxic control cells or
hypoxic cells transfected with control
siRNA (Figures 2E and 2F, P, 0.05).
Induction of HIF-1a in Normoxia
Down-Regulates CD55 Expression
In Vitro
We investigated if HIF-1a induction under
normoxic conditions was sufﬁcient to
suppress CD55 expression. HIF-1a was
stabilized in normoxic SAECs by treating
SAECs with DMOG, a prolyl hydroxylase
(PHD) inhibitor. Preliminary studies
conﬁrmed the optimal dosing and timing
to observe for DMOG-mediated effects
(Figure E3A). Control experiments
conﬁrmed that DMOG stabilized HIF-1a
protein expression in SAECs under
normoxic conditions at 6 hours and
increased signiﬁcantly by 6–24 hours
(Figures 3A and 3B, P, 0.05). Similar
results were observed in SAECs with no
DMOG treatment (0 h) and vehicle control
(data not shown). Therefore, only 0-hour
DMOG treatment results were used to
compare the effects of DMOG. Consistent
with the induction of HIF-1a, CD55
transcripts were down-regulated after
6 hours of DMOG treatment (Figure 3C,
P, 0.01), and CD55 protein down-regulation
was observed at 24 hours (Figures 3D and
3E, P, 0.01). Data showing that CA9
transcripts were signiﬁcantly higher in
DMOG-treated SAECs provide evidence
that DMOG-induced effects are due to
stabilizing HIF-1a (Figure 3F, P, 0.05,
P, 0.01).
To conﬁrm further speciﬁcity of
DMOG-induced effects, we silenced PHD2,
a PHD enzyme with increased selectivity for
HIF-1a ubiquitination and degradation
in normoxia (15, 16). PHD2 siRNA
transfection showed dose-dependent down-
regulation of PHD2 transcripts in normoxic
SAECs that correlated with decreased
protein expression (Figures E4A–E4D,
P, 0.05). However, no signiﬁcant change
in CD55 protein expression was observed
in PHD2 siRNA–transfected normoxic
SAECs versus control siRNA (Figures E4C
and E4E, P, 0.05, P, 0.01). To conﬁrm
that silencing PHD2 results in increased
stabilization of HIF-1a in normoxia, we
assessed and quantiﬁed HIF-1a protein
expression in normoxic SAECs that were
transfected with 50–150 nM PHD2 siRNA
(Figures E5A and E5B). HIF-1a expression
was induced in normoxic SAECs that were
transfected with 50–150 nM PHD2 siRNA
compared with control siRNA (Figures E5A
and E5B, P, 0.05, P, 0.01).
HIF-1a was also stabilized in
normoxic SAECs by transduction with an
AdCA5, an adenoviral vector, to express
constitutively active HIF-1a (10). HIF-1a
expression was signiﬁcantly higher in
AdCA5-transduced normoxic cells at
24 hours compared with HIF-1a basal
levels expressed in normoxic SAECs
transduced with AdLACZ (Figures E6A
and E6B, P, 0.05). AdCA5-induced
HIF-1a correlated with down-regulated
CD55 expression in the same cells
(Figures E6C and E6D, P, 0.05).
Hypoxia Down-Regulates Airway
CD55 In Vivo
CD55 expression was assessed in the lungs
of C57BL/6 mice after 24 hours of hypoxia
(10% O2) in vivo. Analysis of whole-lung
homogenates revealed that CD55 transcript
and protein expression were down-
regulated (Figures 4A–4C, P, 0.01).
Immunohistochemistry (IHC) analysis
revealed that this CD55 down-regulation
occurred in 24-hour hypoxic mouse
airway epithelium (Figure 4D). The
expression of the HIF-1a–dependent
gene, CA9, was also assessed to conﬁrm
the presence of HIF-1a and its activity.
CA9 transcripts were increased in
24-hour hypoxic mouse lungs compared
with lungs of normal mice, thus
indicating hypoxia-induced HIF-1a
activity (Figure 4E, P, 0.05).
Down-Regulation of CD55 in Hypoxic
Mouse Lungs Results in Local
Complement Activation
Due to the CD55 down-regulation observed
in hypoxic mouse lungs (Figure 4), we
assessed local complement activation in
bronchoalveolar lavage ﬂuid (BALF) of
these hypoxic mice as a functional correlate
for the repression of this speciﬁc CRP.
Interestingly, C3a levels were elevated in
the BALF from these 24-hour hypoxic mice
(Figure E7A, P, 0.05).
Silencing HIF-1a In Vivo during
Hypoxia Recovers CD55 Airway
Expression
We next investigated if silencing HIF-1a
expression in vivo could recover CD55 in
hypoxic mouse lungs. After intratracheal
instillation of HIF-1a siRNA or control
siRNA, C57BL/10 mice were placed in
hypoxic conditions (10% O2) for 72 hours.
HIF-1a silencing was conﬁrmed via
densitometry analysis of HIF-1a in whole-
lung homogenates (Figures E8A and E8B,
P, 0.01). IHC analysis also showed a trend
for HIF-1a down-regulation in hypoxic
mouse airways (Figure E8C). CA9
transcription was assessed to conﬁrm the
effect of HIF-1a silencing. CA9 transcripts
were elevated in 24-hour hypoxic mouse
lungs compared with normal lungs (Figure
E8D, P, 0.001), but down-regulated in
24-hour hypoxic mouse lungs treated with
HIF-1a siRNA (Figure E8D, P, 0.05).
Interestingly, CD55 expression was restored
in hypoxic mouse lung homogenates with
HIF-1a siRNA compared with mouse lung
homogenates with control siRNA (Figures
5A and 5B, P, 0.05). IHC analysis
shows recovery of CD55 expression in
HIF-1a–silenced 24-hour hypoxic mouse
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airways (Figure E8C). CD55 recovery was
also observed after 24 hours of hypoxia in
mice that were instilled intratracheally with
chetomin to inhibit HIF-1a (Figures E9A
and E9B, P, 0.01). This was further
conﬁrmed by IHC analysis depicting CD55
recovery observed on airway epithelium of
chetomin-instilled hypoxic mouse lungs
compared with hypoxic mouse lungs with
vehicle control, and the speciﬁcity of the
drug was conﬁrmed by assessing the CA9
transcripts (Figures E9C and E9D).
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Figure 2. Silencing HIF-1a in hypoxic SAECs recovers CD55. (A) HIF-1a is silenced in 6-hour hypoxic SAECs transfected with 50 nM HIF-1a small interfering
RNA (siRNA) versus 6-hour hypoxic SAECs with control siRNA (50 nM) or in normoxia. Lamin b1 was the loading control. (B) HIF-1a was repressed in 24-hour
hypoxic SAECs transfected with HIF-1a siRNA versus control siRNA or normoxic levels. Data represent means (6SEM); n = 3; *P, 0.05 versus normoxia or
control siRNA in 24 hours of hypoxia; one-way ANOVA with Bonferroni posttest. (C) CA9 transcripts were repressed in HIF-1a siRNA–transfected 6-hour
hypoxic SAECs versus 6-hour hypoxic SAECs with or without control siRNA. Values represent means (6SEM); n = 3; **P, 0.01 versus nomoxia, 6 hours of
hypoxia, or control siRNA; one-way ANOVA with Bonferroni posttest. (D) CD55 transcripts were recovered in HIF-1a siRNA–transfected 6-hour hypoxic
SAECs versus 6-hour hypoxic SAECs in the presence or absence of control siRNA. Values represent means (6SEM); n = 3; *P, 0.05 versus nomoxia, 6
hours of hypoxia, or control siRNA; one-way ANOVA with Bonferroni posttest. (E) CD55 was assessed in normoxic, 24-hour hypoxic HIF-1a siRNA, or control
siRNA–transfected SAECs. Vinculin was the loading control. (F) CD55 was recovered in 24-hour HIF-1a siRNA SAECs versus control siRNA or normoxic
levels. Values represent means (6SEM); n = 3; *P, 0.05 versus normoxia, 6 hours of hypoxia, or control siRNA; one-way ANOVA with Bonferroni posttest.
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Induction of HIF-1a In Vivo during
Normoxia Down-Regulates Airway
CD55 Expression
HIF-1a stabilization was achieved in vivo
by intratracheal instillation of DMOG
during normoxia. Compared with
vehicle control, DMOG induced HIF-1a
expression during normoxia (Figures E10A
and E10B, P, 0.05). IHC analysis shows
HIF-1a stabilization in normoxic mouse
airways of mice instilled with DMOG
versus vehicle control airways (Figure
E10C). The speciﬁcity of this effect was
conﬁrmed by data showing increased CA9
in lungs of these mice (Figure E10D,
P, 0.05). HIF-1a stabilization by DMOG
in normoxic mouse lungs by 6 hours resulted
in down-regulation of CD55 transcripts
(Figure 6A, P, 0.01) and protein (Figures
6B and 6C, P, 0.01) compared with
vehicle controls. Suppression of CD55 was
further conﬁrmed by IHC analysis of
DMOG-instilled mouse airways in
comparison to the controls (Figure 6D).
Collectively, these results conﬁrm that
HIF-1a stabilization in the absence of
hypoxia also mediates CD55 down-regulation.
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Discussion
Experimental ﬁndings highlighted in these
studies demonstrate a role for HIF-1a
in regulating airway epithelial CD55
expression. HIF-1a inhibition via chetomin
or siRNA in hypoxic SAECs recovered
CD55 expression and down-regulated the
HIF-1a–dependent gene, CA9, in vitro and
in vivo. In vivo data suggest that CD55
down-regulation in hypoxic mouse lungs
correlated with increases in local
complement activity, as shown by elevated
C3a levels in BALF after 24 hours of
hypoxia. In contrast, stabilizing HIF-1a
in normoxic SAECs through AdCA5, or
in vivo and in vitro through DMOG,
resulted in CD55 down-regulation.
Furthermore, stabilizing HIF-1a expression
by silencing PHD2 during normoxia
down-regulated CD55 expression.
In addition to CD55, other CRPs, such
as CD46/CRRY or CD59, can regulate
complement activation. However, our
studies focused on CD55, due to its uniform
expression on membranes of many cell
types, including airway epithelial cells (17).
CD55, a glycosylphosphatidylinositol-
anchored protein, functions by
preventing/dissociating C3 and C5
convertases, thereby inhibiting complement
activation (18). In addition, CD55 has a
role in protection from natural killer
cell–mediated injury extravasation of
neutrophils in epithelial cells, and is a
receptor for certain viruses (17). Along with
the role in innate immunity, CD55 also
functions in adaptive immunity by having a
costimulatory role in T cell activation and
differentiation (19). Therefore, the observed
CD55 down-regulation in some of these
pulmonary pathologies (3, 5) may
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Figure 4. In vivo, hypoxia results in CD55 down-regulation in mouse lungs. (A) CD55 transcript levels were significantly down-regulated in 24-hour
hypoxic mouse lungs compared with lungs of normal mice. Values represent means (6SEM); n. 6; **P, 0.01 versus normal mice; two-tailed unpaired
t test. (B) CD55 expression was probed for CD55 in lung homogenates of 24-hour normal and hypoxic mice; b-actin was used as the loading control.
(C) Densitometry analysis depicts statistically significant down-regulation of CD55 in 24-hour hypoxic mouse lungs compared with normal mice. Data
represent means (6SEM); n = 4; **P, 0.01 versus normal mice; two-tailed unpaired t test. (D) Immunohistochemistry (IHC) analysis shows CD55
down-regulation in 24-hour hypoxic mouse airways compared with control normal mice. Original magnification: 320. (E) HIF-1a–dependent gene, CA9,
was transcriptionally induced in lungs of 24-hour hypoxic mice compared with normal mice. Values represent means (6SEM); n. 4; *P, 0.05 versus
normal mice; two-tailed unpaired t test.
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exacerbate lung injury through CD55
eliciting innate and adaptive immune
responses.
These ﬁndings may be of particular
interest for understanding the pathogenesis
of pulmonary diseases, such as OB and IPF,
where hypoxia occurs and down-regulation
of CD55 is observed (1, 2). Therefore, it is
possible that HIF-1a induced by airway
hypoxia may contribute to the CD55
down-regulation observed in these
diseases. It is plausible that regulating
HIF-1a expression in these pulmonary
diseases could preserve CD55 expression
on airway epithelium, which could
attenuate complement activation
observed in OB (3) and IPF (5).
To the best of our knowledge, only two
other studies report a link between CD55
and HIF-1a. Colgan and colleagues (20)
reported that HIF-1a induced CD55 on
human colorectal adenocarcinoma cells,
and Collard and colleagues (21) reported a
similar effect on hypoxic human umbilical
vein endothelial cells. These data are in
contrast to the current study, in which
HIF-1a down-regulated CD55 on airway
epithelium, and are likely accounted for by
the use of primary cells in the current study
rather than immortalized cell lines in prior
reports (20–22). In addition, the current
study uses lung cells, whereas the prior
reports used nonlung cells to assess HIF-1a
effects on CD55. These data could suggest
tissue-speciﬁc effects of HIF-1a on CD55
expression. Factors, such as duration of
hypoxic exposure and the concentration of
oxygen used to induce hypoxia, may also
contribute to hypoxia-dependent CD55
expression.
In normoxia, PHDs hydroxylate
proline residues (p402 and p564) on HIF-
1a, enabling E3 ubiquitin ligase, known as
Von Hippel-Lindau, to ubiquitinate and
degrade HIF-1a by 26S proteasome (23).
In hypoxia, PHDs are inactivated, and
HIF-1a is stabilized (23) and translocated
to the nucleus to bind to its constitutively
expressed subunit, HIF-1b. This
heterodimer binds to hypoxia response
elements on the DNA sequence and
assembles with coactivators or corepressors
for target gene activation or repression,
respectively (24). This translocation process
may take some time, which may explain the
temporal lag between induction of HIF-1a
and activation of CA9 (Figure 1). HIF-1a
transcription is constitutive, but basal levels
of HIF-1a in normoxia are observed due
to the cyclical nature of its synthesis and
degradation (23, 25).
Although other forms of PHD enzymes
exist, PHD2 was silenced, due to its selectivity
for HIF-1a among the other HIF isoforms,
and its abundant expression in various cells
(16). Silencing PHD2 resulted in up-regulated
HIF-1a expression, which correlated with
decreased CD55 transcript levels, but not
CD55 protein during normoxia. This
differential expression between CD55
transcripts and protein when PDH2 was
silenced could be due to activity of other
PHD isoforms compensating for the loss
of PHD2. This question will be addressed
in future studies.
Although data in the current study
show that HIF-1a down-regulates
CD55 expression, the exact molecular
mechanisms of this process are not known.
We speculate that transcriptional down-
regulation may occur through epigenetic
modiﬁcations of CD55 by recruitment of
corepressors and histone-modifying
complexes, as indicated by studies where
HIF-1a resulted in transcriptional
repression of other genes (26, 27).
Some of the corepressors involved in
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Figure 5. CD55 expression recovered in hypoxic mouse lungs in which HIF-1a was silenced. (A) CD55 expression was probed for in lung
homogenates of 24-hour hypoxic mice intratracheally instilled with HIF-1a siRNA (50 mg) or control siRNA (50 mg); b-actin was used as
internal loading control. (B) Densitometry analysis indicated that CD55 was restored significantly in lung homogenates of 24-hour hypoxic mice
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silenced compared with hypoxic mouse lungs with control siRNA. Original magnification: 320.
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HIF-1a–mediated gene repression are
characterized as histone deacetylases
(HDACs). Although the formation of the
type of corepressor–HIF-1a complex
depends on the stimulus and speciﬁcity of
the cell or tissue, some of the corepressors
known to bind HIF-1a in hypoxic
conditions include HDAC1, HDAC2,
HDAC3, HDAC4, HDAC5, HDAC7, and
sirtuin-3 (28–32). However, it is likely that
HIF-1a and HDAC interactions, under
certain conditions, can also enhance
transactivation of genes (32, 33). Therefore,
it may be possible that corepressors with
functional characteristics like methylase or
demethylase activity may mediate CD55
down-regulation (34). Although other
isoforms of HIFs exist, such as HIF-2a and
HIF-3a, we focused on HIF-1a for our
studies due to its ubiquitous expression and
its strong induction during hypoxia (24).
However, the current data do not exclude
the possibility of other HIF isoforms in
regulating CD55.
A potential limitation of our study
involves the use of 10% oxygen for in vivo
experiments, and 1% oxygen in vitro. Due
to lethality associated with prolonged
exposure, we were not able to conduct
in vivo studies using 1% oxygen in vivo,
although 10% oxygen is reported
commonly for in vivo rodent studies
(35, 36). The effects of various oxygen
concentrations on CD55 expression
in vitro will be assessed in future
studies.
In summary, these studies highlight
a role for HIF-1a in regulating CD55 on
airway epithelium. It is intriguing to
speculate that targeting the HIF-1a
pathway could be a therapeutic
intervention in lung diseases associated
with complement activation. n
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Figure 6. Induction of HIF-1a results in CD55 down-regulation. (A) CD55 transcript levels were significantly down-regulated in 6-hour lung
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